LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Engineered COVID-19 Antibody Enables Extremely Rapid Identification of SARS-CoV-2 in Nasal Mucus, Saliva, and Blood

By LabMedica International staff writers
Posted on 20 Oct 2020
Print article
Illustration
Illustration
An engineered monoclonal antibody against the COVID-19 virus spike protein could enable extremely rapid identification of the SARS-CoV-2 virus in nasal mucus, saliva, and blood, as well as potentially allow for rapid identification of the virus present on surfaces, such as food, cell phones, door handles, etc., through testing only a small sample.

The new class of anti-spike protein monoclonal antibodies against COVID-19 was created by researchers at Halberd Corporation (Jackson Center, PA, USA) and Arizona State University (ASU Tempe, AZ, USA). Halberd has begun the process of filing the first of multiple planned joint patent applications for this new class of antibody and will not publicly disclose details concerning the rapid identification methodology until appropriate patent protections are in place. Halberd scientists believe that the breakthrough could help solve the COVID-19 pandemic by accelerating identification of the SARS-CoV-2 virus, and the scientific analysis of the effectiveness of COVID-19 therapeutics.

Scientists from Halberd believe that rapid identification is essential to permit effectively initiating therapeutics in the earliest phases of COVID-19. Early identification and treatment could substantially curtail the spread of COVID-19.

“The progress over the past month has been phenomenal and is already yielding patentable intellectual property. We foresee this as just the first of many potential patent applications to address the rapid detection, prevention, and treatment of COVID-19,” said Dr. Patricio Reyes, Chief Technical Officer of Halberd Corporation.

Related Links:
Arizona State University
Halberd Corporation


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS-CoV-2 Test
One Step SARS-CoV-2 Nucleic Acid Detection Kit (P761H)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more